NDARECTALAEROSOL, METERED
Approved
Feb 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
6/8 — Strong
CORTIFOAM (hydrocortisone acetate) by Viatris (2) is clinical pharmacology cortifoam provides effective topical administration of an anti-inflammatory corticosteroid as adjunctive therapy of ulcerative proctitis. Approved for atopic dermatitis. First approved in 1982.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Cortifoam is a metered-dose rectal aerosol containing hydrocortisone acetate, a topical corticosteroid approved in 1982 for adjunctive treatment of ulcerative proctitis. It delivers anti-inflammatory therapy directly to the rectum, with methylene blue studies showing penetration approximately 10 centimeters into the rectal mucosa. The drug is indicated for atopic dermatitis and works through local corticosteroid anti-inflammatory mechanisms.
$0.528MPart D
LOE ApproachingLimited commercial opportunity as product approaches loss of exclusivity with minimal Medicare Part D claims and spending; small brand team likely in transition or maintenance mode.
Mechanism of Action
CLINICAL PHARMACOLOGY Cortifoam provides effective topical administration of an anti-inflammatory corticosteroid as adjunctive therapy of ulcerative proctitis. Direct observations of methylene blue-containing foam have shown staining about 10 centimeters into the rectum.
Indications (1)
Clinical Trials (1)
Pharmacokinetics and Bioavailability of Hydrocortisone Acetate Suppositories
Started Mar 2016
16 enrolled
Healthy
Career Relevance
Cortifoam linked to zero active job postings, reflecting minimal commercial engagement and brand team contraction typical of LOE-stage products. Career prospects on this brand are limited and skew toward cost-optimization, patient-assistance programs, and managed-care negotiation rather than growth-oriented roles.
Worked on CORTIFOAM at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.